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Abstract
Background: Antigen-specific antibody-mediated immune responses play an important role in
natural protection against clinical malaria, but conflicting estimates of this association have emerged
from immuno-epidemiological studies in different geographical settings. This study was aimed at
assessing in a standardized manner the relationship between the antibody responses to four malaria
vaccine candidate antigens and protection from clinical malaria, in a cohort of Ghanaian children.
Methods: Standardized ELISA protocols were used to measure isotype and IgG subclass levels to
Apical Membrane Antigen 1 (AMA1), Merozoite Surface Protein 1–19 (MSP119), Merozoite Surface
Protein 3 (MSP3) and Glutamate Rich Protein (GLURP) antigens in plasma samples from 352
Ghanaian children, aged three to 10 years with subsequent malaria surveillance for nine months.
This is one of a series of studies in different epidemiological settings using the same standardized
ELISA protocols to permit comparisons of results from different laboratories.
Results: The incidence rate of malaria was 0.35 episodes per child per year. Isotype and IgG
subclasses for all antigens investigated increased with age, while the risk of malaria decreased with
age. After adjusting for age, higher levels of IgG to GLURP, MSP119, MSP3 and IgM to MSP119, MSP3
and AMA1 were associated with decreased malaria incidence. Of the IgG subclasses, only IgG1 to
MSP119 was associated with reduced incidence of clinical malaria. A previous study in the same
location failed to find an association of antibodies to MSP119 with clinical malaria. The disagreement
may be due to differences in reagents, ELISA and analytical procedures used in the two studies.
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When IgG, IgM and IgG subclass levels for all four antigens were included in a combined model,
only IgG1 [(0.80 (0.67–0.97), p = 0.018)] and IgM [(0.48 (0.32–0.72), p < 0.001)] to MSP119 were
independently associated with protection from malaria.
Conclusion: Using standardized procedures, the study has confirmed the importance of
antibodies to MSP119 in reducing the risk of clinical malaria in Ghanaian children, thus substantiating
its potential as a malaria vaccine candidate.
Background
Malaria remains one of the most important causes of mor-
bidity and mortality in the world. Current methods of
control are only partially effective and, therefore, the
development of a vaccine which can provide a high degree
of protection is a priority. Antibody-mediated immune
responses to malaria antigens are known to be involved in
protecting against disease [1-4], but the antigens that
induce protective antibodies have not been conclusively
identified. Immuno-epidemiological studies from differ-
ent laboratories have sometimes yielded conflicting
results [5-8]. This may be partly due to differences in
malaria endemicity and the use of different study designs,
reagents, assay protocols and statistical methodologies. In
an attempt to make such studies more comparable, the
Afro-Immuno Assay (AIA) network project was initiated.
The network includes six African Institutions in Gabon,
Ghana, Burkina Faso, Senegal, Tanzania, and Zimbabwe
and three European Institutions from Denmark, The
Netherlands and France. The Afro-Immuno Assay network
has developed standardized enzyme immuno assays [9-
11] that ensure the use of the same reagents, protocols and
statistical methods to assess the association between
acquisition of malaria specific antibody responses to four
potential malaria vaccine candidate antigens and possible
protection from clinical malaria. Samples for the AIA
multi-center project were retrospectively obtained from
cohort studies in six different geographical and epidemio-
logical settings, comprising low endemic to holoendemic
areas. These antigens include the Glutamate Rich Protein
(GLURP), the Merozoite Surface Protein 3 (MSP3) [12],
the 19-kilo Dalton region of the Merozoite Surface Pro-
tein 1 (MSP119) [13] and the Apical Membrane Antigen 1
(AMA1) [14], which are all thought to induce protective
antibody responses through various mechanisms [15-18].
Vaccines incorporating these antigens are currently in clin-
ical trials and are described in detail elsewhere [7,19-26].
It is likely that a future malaria vaccine will comprise mul-
tiple rather than single antigens and it is, therefore, useful
to study natural immune responses to multiple malaria
antigens in relation to incidence of malaria in a more
standardized way. In this study, the standardized AIA
ELISA procedures [9-11], were used to assess the relation-
ship between incidence of clinical malaria and naturally
acquired isotype and IgG subclass responses to these four
leading malaria vaccine candidate antigens, AMA1,
MSP119, MSP3 and GLURP in Ghanaian children from
three to 10 years of age.
Materials and methods
Study area, study population and morbidity surveillance
Samples used in this study were obtained in March 2002
from a longitudinal study conducted in Dodowa, in
which 352 children aged three to 10 years (in the active
phase of acquiring immunity to malaria), were enrolled in
a study, whose original aim had been to assess the role of
cytokine regulation and immunity to malaria. Dodowa is
a semi-rural town in the Dangme West District of the
Greater Accra Region of Ghana, about 50 km from the
capital Accra and is an area of moderate and stable
malaria transmission with a seasonal peak. Bed net cover-
age in this area was low, about 10% [27]. The study was
approved by the Noguchi Memorial Institute's Ethical
Review Board. After obtaining consent from parents,
blood was obtained from each child and plasma stored at
-20°C until use. Malaria episodes were detected using
both active and passive surveillance implemented over a
period of nine-months, spanning the entire malaria trans-
mission season. Clinical and parasitological information
was captured using a standard questionnaire. Each child
was visited once a week and the child and the parents or
guardians were asked about symptoms of malaria since
the last visit and whether she/he had received any anti-
malarial treatment. The child was then given a physical
examination and the body temperature measured. Chil-
dren with a history of fever within 48 hours and/or axil-
lary temperature equal to or above 37.5°C had a rapid test
for malaria parasitaemia using OptiMAL™ (DiaMed,
FLOW Inc. Portland, Oregon) and then thick and thin
blood films were prepared for microscopy for estimating
the parasite density which was used later in the more spe-
cific malaria case definition employed for data analysis.
Only children with measured or reported fever, and with
a positive rapid test were treated with chloroquine (in
accordance with the then prevailing national malaria
treatment policy) and in the case of severe symptoms, the
child was referred to the hospital. At monthly intervals,
blood smears from finger pricks were obtained from all
children irrespective of symptoms to estimate the preva-
lence of asymptomatic malaria infections. The parents of
the children were instructed to report to the field team if
the child had any symptoms of disease at any time. The
Malaria Journal 2008, 7:142 http://www.malariajournal.com/content/7/1/142
Page 3 of 11
(page number not for citation purposes)
qualifying case definition for malaria in the data analysis
was reported fever and/or a measured temperature equal
to or above 37.5°C, with parasitaemia ≥ 5,000 parasites/
μl of blood; this case definition has been found to have
90% sensitivity and specificity in the study area [28-30].
Positive and negative control plasma used in ELISA meas-
urements were obtained from adult Liberians and Danes
respectively.
Malaria antigens
AMA1 was from the Pichia pastoris expressed ectodomain
of Plasmodium falciparum FVO strain comprising amino
acids 25–545 [31] (Donated by A Thomas, Biomedical
Primate Research Centre). GLURP was an Escherichia coli
recombinant protein containing the conserved non-
repeat N-terminal region (amino acids 25–514) called R0
[32] (Donated by M. Theisen, Statens Serum Institut).
MSP119 was a Baculovirus antigen of the C-terminal region
of the merozoite protein surface 1, produced in insect cells
infected with a recombinant Baculovirus containing a syn-
thetic G-C enriched PfMSP1 gene (Palo Alto allele), cod-
ing for 43 N-terminal MSP1 precursor residues and 16
amino acid residues upstream of the "classical" MSP-119
(NIS---FCS) [33] (Donated by S. Longacre, Institut Pas-
teur). The MSP3 antigen used in this study was a long syn-
thetic peptide called LR55 (amino acids 181 – 276) of the
merozoite surface protein 3 [34] (Donated by M. Theisen,
Statens Serum Institut). All the antigens were provided
through the AIA Project.
Enzyme-linked immunosorbent assay (ELISA)
Specific isotype and IgG subclass levels against GLURP,
MSP119, MSP3 and AMA1 were measured using indirect
ELISA according to the AIA standard ELISA protocols [9-
11]. All antigens tested were optimized and shown to be
stable for at least three weeks, when antigen-coated plates
and serum/plasma dilutions are refrigerated. The subclass
specific reagents used were selected on the basis of low
cross reactivities among themselves. To control for inter-
assay and day-to-day variations in the standardized ELISA
procedure, three-fold serial dilutions of reference stand-
ard reagents (IgG, IgM and IgG1 to IgG4) were directly
coated on each ELISA plate (Maxisorp Nunc, Denmark) at
a start concentration of 1,000 ng/ml (100 μl/well). OD
values for the test samples were converted into antibody
units with the standard reference curves generated for
each ELISA plate using a four parameter curve-fit Micro-
soft Excel-based application. Samples were re-tested if the
coefficient of variation between duplicate absorbance val-
ues were higher than 15% and plates were also re-tested if
the R-square value of the standard curve was less than
97%. The reference standards, PBS buffer blank, positive
and negative control plasma pools that were included in
each ELISA test plate allow for the determination of failed
assay runs. The AIA ELISA procedure used in this study is
described in detail elsewhere [10].
Statistical analysis
Clinical data were double entered using Microsoft Fox Pro
and immunological data using Excel. STATA version 9.2
(Statcorp, Texas) was used for statistical analysis. Children
were considered to have a clinical malaria episode if they
had parasitaemia of ≥ 5,000 parasites/μl, with a measured
temperature ≥ 37.5°C or a history of fever in the last 48
hours [6,35,36].
For each antigen, Poisson regression was used to investi-
gate the association between the levels of antibody meas-
ured at baseline and the incidence rate of the first (or
only) episode of clinical malaria. The level of total IgG,
IgM and each IgG subclass, were analysed for each antigen
in turn. Antibody values were transformed to log base 2,
so that the rate ratio represents the ratio of malaria inci-
dence corresponding to a doubling of antibody level. To
investigate whether the relationship between malaria inci-
dence and antibody level was nonlinear, a likelihood ratio
test was used to compare the fit of the model when anti-
body level was included as a categorical or a continuous
variable. When there were zero antibody values, indicat-
ing levels below the detection limit, the zero (left cen-
sored) values were assigned a nominal value equal to half
the smallest measured value for that variable. If the pro-
portion of zero values was large, the variable was treated
as categorical with the reference category containing the
zero values and the positive values divided into three
equal groups. A likelihood ratio test was used to deter-
mine the P-value for the association with malaria inci-
dence. Age at enrolment was considered to be an
important potential confounder, and was included in the
regressions as a factor with categories defined by quintiles.
To model seasonality in malaria incidence, the calendar
month of surveillance was included in the models as a fac-
tor. To construct a parsimonious model using all the
immunological variables, firstly a model was produced
for each antigen; in this model each IgG subclass, total IgG
and IgM were candidates for inclusion provided the P-
value for association with malaria incidence was 0.1 or
less when considered individually. Variables were then
removed from the model if the P-value for the likelihood
ratio test was more than 0.1, provided removal did not
change coefficients of variables in the model by more than
10%. In a second stage, the variables included in these
models were candidates for inclusion in a final model
derived in a similar way. Baseline parasitaemia was not
considered as a potential confounder, but the interaction
between each immunological variable and the presence of
parasitaemia at baseline in their effects on malaria inci-
dence was examined. A consequence of using a more spe-
cific case definition in the analysis than was used to decide
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treatment during the study is that children could have
received anti-malarial treatments during the period they
are considered at risk in the analysis. To explore the
impact of these drug treatments, a time dependent varia-
ble was defined, to allow for a reduced risk of malaria for
a period of 28 days after each drug treatment, which was
included as a covariate in the Poisson regression model.
LOESS smoothing was applied in R software to plot anti-
body levels in relation to age. Spearman's rank correlation
test was used to assess associations between antibody lev-
els and age.
Results
Pattern of P. falciparum infections and malaria in the 
study cohort
Of the 352 children recruited for the original study, eight
were lost to follow-up immediately after the baseline
blood sampling. Of the 344 children followed up, sixty
four (19%) had at least one episode of malaria (53 chil-
dren had one episode, nine had two and two had three
episodes). The incidence rate of malaria in the study
cohort was 0.35 attacks per child per year (Table 1). The
risk of clinical malaria decreased with increasing age [37].
Sixty-six percent of the children had asymptomatic parasi-
taemia at baseline. Parasites were predominantly P. falci-
parum (95%) and the prevalence of parasitaemia
measured each month was roughly constant (ranging
from 50% to 65%). The incidence of clinical malaria,
however, varied during the survey period, rising gradually
from March to May, peaking in July and then decreasing
until November (Figure 1).
Relationship between age and antibody levels
Several studies in malaria endemic regions have shown
increasing antibody levels with age. This pattern is more
pronounced the greater the intensity and duration of
malaria transmission. In this study, the relationship
between antibody levels and age were assessed for anti-
bodies against MSP119, AMA1, GLURP and MSP3. The
levels of IgG and IgM to MSP119, MSP3, AMA1 and
GLURP increased with age (Spearman correlation coeffi-
cient (rs) 0.21 – 0.45; p < 0.001, Figure 2). IgG levels to
AMA1 however, gradually increased until six years of age,
and then leveled off. For the four antigens tested, IgG1,
IgG2 and IgG3 significantly increased with age (rs, 0.12 –
0.36; p < 0.03) with the exception of IgG2 to AMA1. There
was no evidence that the level of IgG4 was associated with
age for any of the antigens. Like IgG to AMA1, IgG3 to
MSP3 steadily increased with age until seven years of age,
then leveled off (Figure 3).
The levels of both IgG and IgG1 were highest for AMA1
and lowest for MSP3, whereas IgG levels to MSP119 and
GLURP were comparable (Figures 2 and 3). The levels of
IgG3 were higher in AMA1 than the comparable levels in
GLURP, MSP119 and MSP3 (Figure 3). In general, the lev-
els of cytophilic IgG1 and IgG3 were higher than those of
non-cytophilic IgG2 and IgG4, IgG4 levels being the low-
est.
Antibody levels in relation to protection from clinical 
malaria
Total IgG to MSP3, MSP119, and GLURP, and IgM to all
four antigens tested (MSP3, MSP119, GLURP, and AMA1)
were associated with reduced malaria incidence in crude
analyses (Table 2). The incidence of both clinical malaria
and antibody levels were associated with age, age is there-
fore a potential confounder, and it is important to adjust
for its effects. After adjusting for the effect of age, there was
evidence of a significant association between total IgG to
MSP3, MSP119, GLURP and reduced risk of malaria (IgG
to MSP3: rate ratio 0.69 (95%CI 0.53, 0.90) P = 0.01; IgG
to MSP119: 0.75 (0.61, 0.92) P = 0.01; IgG to GLURP: 0.79
(0.64, 0.98) P = 0.04); and IgM levels to AMA1, MSP3,
MSP119 were also significantly associated with reduced
risk of malaria (Table 2).
A large proportion of the measurements of IgG4 to MSP3
and AMA1 and IgG2 to AMA1 were zero (left-censored)
values and so these variables were treated as categorical
variables (Table 3). In the crude analysis, IgG1, IgG2 and
IgG3 to MSP3, MSP119, GLURP and also IgG4 to MSP3,
were associated with a reduced risk of clinical malaria
(Table 3, 4), but after adjustment for age, only one of
these variables, IgG1 to MSP119, remained significantly
Table 1: Malaria incidence by age group
Age in yrs: No. of
 children
Cum. incidence
 of malaria
no episodes of malaria
 (years at risk)
Incidence rate per 
child year (95%CI)
3 32 12/32 (38%) 15 (19.52) 0.79 (0.48–1.31)
4–5 86 24/86 (28%) 28 (54.75) 0.51 (0.35–0.74)
6–7 79 11/79 (14%) 13 (51.38) 0.25 (0.15–0.44)
8 48 6/48 (13%) 7 (31.11) 0.22 (0.11–0.47)
9–10 99 11/99 (11%) 14 (61.22) 0.23 (0.14–0.39)
Total 344 64/344 (19%) 77 (217.48) 0.35 (0.28–0.44)
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associated with malaria incidence (rate ratio 0.89 (95%CI
0.80, 0.99), P = 0.04, Table 4).
When all immunological variables were considered
simultaneously, only two variables were independently
associated with reduced malaria incidence, IgG1 [(0.80
(0.66–0.96), p = 0.018)] to MSP119, and IgM [(0.48
(0.32–0.72), p < 0.001)] to MSP119 (Table 5).
The estimated rate ratio for the effect of antimalarial treat-
ments given to children with parasitaemia < 5000/uL was
0.25 (95%CI 0.06–1.05), indicating these children had a
substantially reduced risk of being found positive with
parasitaemia >= 5000/ul during the 28 days following the
treatment. But the estimates of rate ratios for other varia-
bles in the model were unchanged when this variable was
included in the model suggesting treatment effects did not
cause a bias in the estimation of the effects of immunolog-
ical variables.
Discussion
This study in Ghanaian children is one of a series of stud-
ies designed to assess, using standardized methods, the
association of antibody levels to four leading asexual
blood-stage malaria antigens (MSP119, MSP3, AMA1 and
GLURP) with the incidence of clinical malaria in different
epidemiological settings. Previous results have been diffi-
cult to interpret due to different study protocols and ana-
lytical methods having been used [5-7,9,14,29,38-40]. In
this study, the prevalence of asymptomatic malaria para-
sitaemia was relatively high and stable, while incidence of
clinical malaria fluctuated in parallel with the intensity of
transmission and seasonal rainfall pattern. These patterns
are typical of this area and have been reported in previous
The monthly point prevalence of asymptomatic malaria parasitaemia and incident rate of clinical malariaFigure 1
The monthly point prevalence of asymptomatic malaria parasitaemia and incident rate of clinical malaria. The 
point prevalence of asymptomatic parasitaemia for each month is represented as a bar graph and the pattern of clinical malaria 
(incident rate) is shown as a line graph.
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studies [6,41-43]. The variation in the incidence of clinical
malaria during the study period may be due to the intro-
duction of new parasites with different antigenic presenta-
tion into the population leading to clinical malaria in
susceptible individuals. The risk of malaria decreased with
age, while isotype and IgG subclass levels to the four anti-
gens generally increased with age. This is consistent with
the hypothesis that immunity to malaria is largely effected
through antibody-mediated mechanisms and that protec-
tive antibody levels to relevant antigens increase with age-
related exposure to the parasites [44]. Increasing IgG and
IgM levels with age may reflect greater cumulative expo-
sure of older children but may also be due to older chil-
dren having a more mature immune system [45]. The
association of IgM responses with reduced malaria inci-
dence indicates a possible role in immunity in Ghanaian
children. Although much emphasis has been placed on
IgG as the important isotype in immunity against malaria,
IgM, which has lower affinity but is multivalent, may
afford protection via other mechanisms such as the block-
ing of merozoite invasion of erythrocytes, complement
activation, agglutination of merozoites [46].
The association with malaria incidence of IgG responses
to MSP3, MSP119 and GLURP is consistent with data from
several other immuno-epidemiological studies [5,7-
9,12,29,30,38,47-49] indicating that these antigens may
be targets of protective antibodies [1,2,4]. There was no
evidence that IgG levels to AMA1 were associated with
malaria incidence, and there was no evidence of an inter-
action with baseline parasitaemia in contrast with similar
studies conducted in Kenya [14]. As shown in other stud-
ies, the cytophilic antibody levels to the four antigens
tested in this study were higher than the non-cytophilic
ones, emphasizing their importance in anti-malaria
immunity [9,29,38,50,51]. IgG and cytophilic antibody
levels were highest for AMA1, while the levels were rela-
tively low for MSP3. These differences in specific antibody
levels may be related to the number of immunogenic B-
Cell epitopes exposed to the immune system and could
also be related to the structure, location and function of
the particular antigen(s). With the exception of IgG2 lev-
els to AMA1, IgG2 levels to GLURP, MSP119 and MSP3
increased with age which may suggest that IgG2 is
involved in immunity against malaria. In recent studies,
malaria antigen specific IgG2 have been shown to bind
with high affinity to mutant Fcγ RII H131->R receptors
[52] on monocytes, granulocytes and B cells, thus afford-
ing protection against malaria through monocytes and or
neutrophil mediated mechanisms in subjects expressing
the mutant CD32 form [53]. There was however, no evi-
dence found that IgG2 was associated with malaria inci-
dence for any of the four antigens tested.
The IgG subclasses, IgG1, IgG2 and IgG3 for MSP3,
MSP119, GLURP and IgG4 to MSP3 were associated with a
reduced risk of malaria in un-adjusted analysis but of
these only IgG1 to MSP119 was independently associated
Baseline IgG and IgM levels in relation to ageFigure 2
Baseline IgG and IgM levels in relation to age. The top and bottom panels represents total IgG or IgM levels to AMA1, 
GLURP, MSP119 and MSP3 in relation to age of Ghanaian children, respectively. The line shows the LOESS smoothed estimate 
of the geometric mean.
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with malaria incidence after adjustment for age. Other
studies have shown the importance of IgG1 in clearing
parasitaemia in children [5,47,54] In a previous cohort
study conducted in the same area, there was no associa-
tion between antibody levels to MSP119 and malaria inci-
dence [6]. This may be due to differences in antigen and
antibody reagents used in the two studies; the MSP119
used in this study was a Baculovirus product that included
a synthetic G-C enriched PfMSP1 gene that coded for the
43 N-terminal MSP1 precursor residues and 16 amino
acid residues upstream of the "classical" MSP-119 (NIS---
FCS) [33] compared to the one produced in E. coli, which
had been used in the previous study. Although antibodies
to MSP119 have been shown to be associated with both
exposure and protection from disease, the fine specifici-
ties of such responses may contribute to protection [40].
The antigen used in this study may have assessed antibod-
ies of fine specificities that are protective [40,55,56],
whereas the antigen used in the previous study did not. It
may, therefore, be important to assess in a standardized
Baseline IgG subclass levels in relation to ageFigure 3
Baseline IgG subclass levels in relation to age. The top, 2nd, 3rd and 4th panels represent IgG subclasses 1 to 4 against 
AMA1, GLURP, MSP119 and MSP3 in relation to age of Ghanaian children, respectively. The line shows the LOESS smoothed 
estimate of the geometric mean.
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Table 2: Association of total IgG and IgM with malaria incidence
IgG Crude IRR (95%CI) P-value IRR adjusted for age (95%CI) P-value
MSP3 0.59 (0.45, 0.76) < 0.0001 0.69 (0.53, 0.90) 0.01
MSP119 0.74 (0.63, 0.88) < 0.0001 0.75 (0.61, 0.92) 0.01
GLURP 0.68 (0.55, 0.82) < 0.0001 0.79 (0.64, 0.98) 0.04
AMA1 0.96 (0.84, 1.09) 0.50 1.03 (0.89, 1.20) 0.67
IgM:
MSP3 0.62 (0.49, 0.80) < 0.0001 0.76 (0.59, 0.97) 0.03
MSP1 0.59 (0.47, 0.75) < 0.0001 0.68 (0.53, 0.88) < 0.01
GLURP 0.71 (0.58, 0.87) < 0.01 0.84 (0.68, 1.03) 0.09
AMA1 0.48 (0.34, 0.67) < 0.0001 0.63 (0.44, 0.91) 0.01
Malaria incidence rate ratios (IRR) with 95% confidence interval, corresponding to a doubling of baseline antibody level, before and after adjustment 
for the effect of age.
Table 3: Association of IgG2 and IgG4 with malaria incidence.
Antigen Antibody Crude IRR (95%CI) P-value Age-adjusted IRR P-value
MSP3
IgG2* (coded as log(2)) 0.74 (0.57, 0.98) 0.04 0.85 (0.63, 1.15) 0.29
IgG4 < detection limit 1 0.01 1 0.20
< median 0.45 (0.21, 0.95) 0.56 (0.26, 1.19)
≥ median 0.47 (0.28, 0.79) 0.68 (0.40, 1.15)
MSP119
IgG2* (coded as log(2)) 0.62 (0.45, 0.86) < 0.01 0.836 (0.606, 1.157) 0.275
IgG4* (coded as log(2)) 1.07 (0.95, 1.21) 0.25 0.838 (0.608, 1.159) 0.278
GLURP
IgG2* (coded as log(2)) 0.65 (0.49, 0.86) < 0.01 0.79 (0.58, 1.08) 0.13
IgG4* (coded as log(2)) 0.94 (0.81, 1.08) 0.37 1.01 (0.87, 1.16) 0.94
AMA1
IgG2 < detection limit 1 0.18 1 0.54
< median 1.80 (0.86, 3.78)
≥ median 1.78 (0.90, 3.51)
IgG4 < detection limit 1 0.19 1 0.54
< median 0.96 (0.47, 1.93)
≥ median 0.62 (0.36, 1.07)
For IgG 2 to AMA1 and for IgG4 to AMA1 and MSP3, antibody level was categorized.
*For IgG2 to MSP3, MSP119 and GLURP, the association is expressed as the incidence rate ratio (IRR) corresponding to a doubling of baseline 
antibody level.
Table 4: Association of IgG1 and IgG3 with malaria incidence
IgG1: Crude IRR
 (95%CI)
P-value IRR adjusted for age
 (95%CI)
P-value
MSP3 0.82 (0.72, 0.94) < 0.01 0.88 (0.76, 1.03) 0.11
MSP119 0.86 (0.77, 0.97) 0.01 0.89 (0.80, 0.99) 0.04
GLURP 0.85 (0.74, 0.98) 0.02 0.93 (0.81, 1.08) 0.35
AMA1 0.95 (0.86, 1.06) 0.36 1.01 (0.90, 1.14) 0.83
IgG3:
MSP3 0.90 (0.82, 0.98) 0.01 0.94 (0.86, 1.03) 0.17
MSP119 0.90 (0.82, 0.99) 0.03 0.93 (0.84, 1.03) 0.18
GLURP 0.83 (0.74, 0.93) < 0.01 0.91 (0.80,1.03) 0.14
AMA1 0.97 (0.89, 1.06) 0.48 0.98 (0.90, 1.07) 0.73
The incidence rate ratio (IRR) corresponds to a doubling of baseline antibody level, before and after adjustment for effects of age
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way the various MSP119, and other antigens, that are pro-
duced in different expression systems, in order to select
the most appropriate antigen/expression system for
malaria vaccine development. In another study in this
series, in Burkina Faso, the same antigens, reagents, ELISA
procedure and analytical methods were used; none of the
isotypes and subclasses to MSP119 was associated with the
incidence of clinical malaria. Since the same laboratory
methods were used, the different outcomes of these two
studies may be attributed to differences in malaria trans-
mission or to the age of the children [44]. In Burkina Faso,
the malaria transmission season is much shorter, which
may influence the induction of differing antibody types
for controlling malaria as shown in recent studies con-
ducted in areas with different malaria endemicities in Tan-
zania [9,44]. Although total IgG to GLURP and MSP3
were associated with the risk of malaria, none of the con-
stituent subclasses was identified to be associated with
protection. When the effects of all the immunological var-
iables were considered simultaneously, only IgG1 and
IgM to MSP119 were independently associated with the
incidence of clinical malaria, which may indicate the
importance of MSP119 in malaria vaccine development.
Parasite growth inhibition assays would be required to
confirm if this association reflects a functional role of
MSP119 in immunity.
Conclusion
In conclusion, using standardized AIA ELISA, anti-MSP19
antibodies (IgG1 and IgM) have been shown to be the
most strongly correlated with reduced risk of clinical
malaria among the four malaria vaccine candidates tested.
The standardized AIA ELISA developed for this project
could be used to validate malaria vaccine candidate anti-
gens, provide useful baseline information for clinical tri-
als, and contribute to quality assured laboratory capacity
in Africa.
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